Uso universal da vacina inativada contra poliomielite
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0021-75572006000400009 http://repositorio.unifesp.br/handle/11600/3145 |
Resumo: | OBJECTIVES: To present an update on the status of poliomyelitis worldwide, number of cases per year, regions most affected by the disease, vaccines currently available, their risks and benefits, monovalent vaccine use, risks of disseminating a mutant virus in the community, progress that has been made in terms of worldwide eradication and the World Health Organization.s (WHO) proposals in this transition period between global eradication and the post-eradication period. SOURCES OF DATA: Data for the period from 1955 to 2005 were searched in MEDLINE, LILACS, The Web, Doctor's Guide, WHO website and Pan American Health Organization (PAHO) website and text book. SUMMARY OF THE FINDINGS: In 1988, the WHO established the goal of eradicating the disease and interrupting transmission of the wild virus globally. Since then, there has been a dramatic decline of the disease, although in 2005 there were still some countries considered endemic and others where polio returned on account of imported viruses. The vaccines used worldwide are the classical tOPV and IPV, and in this eradication process, the use of mOPV vaccines has been encouraged in places where only one type of poliovirus circulates. In addition to spreading the virus in the community, the OPV vaccines may, however, cause paralyses by reversal of the neurovirulence process. CONCLUSIONS: For a world free of poliomyelitis disease, it would be necessary to interrupt circulation of the virus, which will only be possible if the OPV virus were to be discontinued, in accordance with the WHO proposals for this transition period and the post-eradication period. |
id |
UFSP_7d97dc1c1163fccb4380b27a2d19b4fb |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/3145 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Uso universal da vacina inativada contra poliomieliteUniversal use of inactivated polio vaccinePoliomyelitisOPV vaccineIPV vaccineeradication of poliopolio epidemicpoliomyelitisWord Health OrganizationPoliomielitevacina OPVvacina IPVerradicação de pólioepidemia de póliopoliomieliteOrganização Mundial da SaúdeOBJECTIVES: To present an update on the status of poliomyelitis worldwide, number of cases per year, regions most affected by the disease, vaccines currently available, their risks and benefits, monovalent vaccine use, risks of disseminating a mutant virus in the community, progress that has been made in terms of worldwide eradication and the World Health Organization.s (WHO) proposals in this transition period between global eradication and the post-eradication period. SOURCES OF DATA: Data for the period from 1955 to 2005 were searched in MEDLINE, LILACS, The Web, Doctor's Guide, WHO website and Pan American Health Organization (PAHO) website and text book. SUMMARY OF THE FINDINGS: In 1988, the WHO established the goal of eradicating the disease and interrupting transmission of the wild virus globally. Since then, there has been a dramatic decline of the disease, although in 2005 there were still some countries considered endemic and others where polio returned on account of imported viruses. The vaccines used worldwide are the classical tOPV and IPV, and in this eradication process, the use of mOPV vaccines has been encouraged in places where only one type of poliovirus circulates. In addition to spreading the virus in the community, the OPV vaccines may, however, cause paralyses by reversal of the neurovirulence process. CONCLUSIONS: For a world free of poliomyelitis disease, it would be necessary to interrupt circulation of the virus, which will only be possible if the OPV virus were to be discontinued, in accordance with the WHO proposals for this transition period and the post-eradication period.OBJETIVOS: Apresentar uma atualização da situação da poliomielite no mundo, número de casos anuais, regiões mais atingidas pela doença, vacinas disponíveis na atualidade, seus riscos e benefícios, utilização da vacina monovalente, riscos da disseminação de um vírus mutante na comunidade, progressos que têm sido realizados em termos de erradicação mundial e as propostas da Organização Mundial da Saúde (OMS) nesse período de transição entre a erradicação global e o período pós-erradicação. FONTE DE DADOS: Foram consultadas bases de dados no período de 1955 a 2005 em MEDLINE, LILACS, The Web, Doctor's Guide; site da OMS e Organização Pan-Americana da Saúde (OPAS) e livro-texto. SÍNTESE DOS DADOS: Em 1988, a OMS estabeleceu como meta a erradicação da doença e a interrupção da transmissão do vírus selvagem globalmente. Desde então, houve um dramático impacto no declínio da doença, embora em 2005 ainda existam alguns países considerados endêmicos e outros onde a pólio retornou, por conta de vírus importados. As vacinas utilizadas no mundo são as clássicas tOPV e IPV e, dentro desse processo de erradicação, o uso de vacinas mOPV tem sido estimulado nos locais em que circula apenas um tipo de poliovírus. Entretanto, as vacinas OPV, além de disseminarem o vírus na comunidade, podem causar paralisias por reversão do processo de neurovirulência. CONCLUSÕES:Para um mundo livre da doença poliomielite, será preciso retirar o vírus de circulação, o que só será possível se a vacina OPV for descontinuada, conforme propostas da OMS para esse período de transição e para a era pós-erradicação.Faculdade de Medicina de MaríliaFaculdade de Medicina Metropolitana de SantosSociedade Brasileira de Pediatria Departamento de InfectologiaInstituto de Infectologia Emílio RibasUniversidade Federal de São Paulo (UNIFESP) Escola Paulista de MedicinaUNIFESP-EPM Centro de Referência para Imunobiológicos EspeciaisSecretaria da Saúde do Estado de São PauloUNIFESP, EPM, Centro de Referência para Imunobiológicos EspeciaisSciELOSociedade Brasileira de PediatriaFaculdade de Medicina de MaríliaFaculdade de Medicina Metropolitana de SantosSociedade Brasileira de Pediatria Departamento de InfectologiaInstituto de Infectologia Emílio RibasUniversidade Federal de São Paulo (UNIFESP)Secretaria da Saúde do Estado de São PauloCarvalho, Luiza Helena FalleirosWeckx, Lily Yin [UNIFESP]2015-06-14T13:36:18Z2015-06-14T13:36:18Z2006-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersions75-s82application/pdfhttp://dx.doi.org/10.1590/S0021-75572006000400009Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 3, p. s75-s82, 2006.10.1590/S0021-75572006000400009S0021-75572006000400009.pdf0021-7557S0021-75572006000400009http://repositorio.unifesp.br/handle/11600/3145porJornal de Pediatriainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T15:36:11Zoai:repositorio.unifesp.br/:11600/3145Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T15:36:11Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Uso universal da vacina inativada contra poliomielite Universal use of inactivated polio vaccine |
title |
Uso universal da vacina inativada contra poliomielite |
spellingShingle |
Uso universal da vacina inativada contra poliomielite Carvalho, Luiza Helena Falleiros Poliomyelitis OPV vaccine IPV vaccine eradication of polio polio epidemic poliomyelitis Word Health Organization Poliomielite vacina OPV vacina IPV erradicação de pólio epidemia de pólio poliomielite Organização Mundial da Saúde |
title_short |
Uso universal da vacina inativada contra poliomielite |
title_full |
Uso universal da vacina inativada contra poliomielite |
title_fullStr |
Uso universal da vacina inativada contra poliomielite |
title_full_unstemmed |
Uso universal da vacina inativada contra poliomielite |
title_sort |
Uso universal da vacina inativada contra poliomielite |
author |
Carvalho, Luiza Helena Falleiros |
author_facet |
Carvalho, Luiza Helena Falleiros Weckx, Lily Yin [UNIFESP] |
author_role |
author |
author2 |
Weckx, Lily Yin [UNIFESP] |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Faculdade de Medicina de Marília Faculdade de Medicina Metropolitana de Santos Sociedade Brasileira de Pediatria Departamento de Infectologia Instituto de Infectologia Emílio Ribas Universidade Federal de São Paulo (UNIFESP) Secretaria da Saúde do Estado de São Paulo |
dc.contributor.author.fl_str_mv |
Carvalho, Luiza Helena Falleiros Weckx, Lily Yin [UNIFESP] |
dc.subject.por.fl_str_mv |
Poliomyelitis OPV vaccine IPV vaccine eradication of polio polio epidemic poliomyelitis Word Health Organization Poliomielite vacina OPV vacina IPV erradicação de pólio epidemia de pólio poliomielite Organização Mundial da Saúde |
topic |
Poliomyelitis OPV vaccine IPV vaccine eradication of polio polio epidemic poliomyelitis Word Health Organization Poliomielite vacina OPV vacina IPV erradicação de pólio epidemia de pólio poliomielite Organização Mundial da Saúde |
description |
OBJECTIVES: To present an update on the status of poliomyelitis worldwide, number of cases per year, regions most affected by the disease, vaccines currently available, their risks and benefits, monovalent vaccine use, risks of disseminating a mutant virus in the community, progress that has been made in terms of worldwide eradication and the World Health Organization.s (WHO) proposals in this transition period between global eradication and the post-eradication period. SOURCES OF DATA: Data for the period from 1955 to 2005 were searched in MEDLINE, LILACS, The Web, Doctor's Guide, WHO website and Pan American Health Organization (PAHO) website and text book. SUMMARY OF THE FINDINGS: In 1988, the WHO established the goal of eradicating the disease and interrupting transmission of the wild virus globally. Since then, there has been a dramatic decline of the disease, although in 2005 there were still some countries considered endemic and others where polio returned on account of imported viruses. The vaccines used worldwide are the classical tOPV and IPV, and in this eradication process, the use of mOPV vaccines has been encouraged in places where only one type of poliovirus circulates. In addition to spreading the virus in the community, the OPV vaccines may, however, cause paralyses by reversal of the neurovirulence process. CONCLUSIONS: For a world free of poliomyelitis disease, it would be necessary to interrupt circulation of the virus, which will only be possible if the OPV virus were to be discontinued, in accordance with the WHO proposals for this transition period and the post-eradication period. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-07-01 2015-06-14T13:36:18Z 2015-06-14T13:36:18Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0021-75572006000400009 Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 3, p. s75-s82, 2006. 10.1590/S0021-75572006000400009 S0021-75572006000400009.pdf 0021-7557 S0021-75572006000400009 http://repositorio.unifesp.br/handle/11600/3145 |
url |
http://dx.doi.org/10.1590/S0021-75572006000400009 http://repositorio.unifesp.br/handle/11600/3145 |
identifier_str_mv |
Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 3, p. s75-s82, 2006. 10.1590/S0021-75572006000400009 S0021-75572006000400009.pdf 0021-7557 S0021-75572006000400009 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Jornal de Pediatria |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
s75-s82 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Pediatria |
publisher.none.fl_str_mv |
Sociedade Brasileira de Pediatria |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268401756930048 |